NBSE - NeuBase Therapeutics Inc Stock Price, Fair Value and News

$0.38

Market Closed

NBSE Stock Valuation Analysis

Valuation

Max Portfolio %

NBSE Price Action

NBSE RSI Chart

NBSE Stock Valuation Analysis

Valuation

Max Portfolio %

NBSE Valuation

NBSE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NBSE Fundamentals

NBSE Revenue

NBSE Earnings

NBSE Profitability

NBSE Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	407.5K	533.3K	0
2022	80.6K	114.6K	148.6K	294.9K
2021	28.1K	20.3K	12.6K	46.6K
2015	800.2K	418.0K	35.8K	0
2014	962.2K	1.5M	1.6M	1.2M
2013	959.7K	1.0M	1.1M	0
2012	0	0	875.9K	0
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

CEO	Dr. Dietrich A. Stephan Ph.D.
WEBSITE	neubasetherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	37